GlassScriptPhysician profile
Indira R Asser
NPI 1043414048
$4,374.24
in general payments reported to CMS, 2019-2025
30 companies · $1,392 in 2025
The $1,392 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $876 · 2020: $136 · 2021: $50.80 · 2022: $11.71 · 2023: $947 · 2024: $961 · 2025: $1,392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,299.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $695.48 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $605.49 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $449.47 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $325.71 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $269.02 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $246.54 | 2019-2025 | Jardiance, Ofev |
| Otsuka America Pharmaceutical, INC. | $237.67 | 2023-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $223.20 | 2019-2024 | Xarelto |
| Astellas Pharma US INC | $190.99 | 2024-2025 | Veozah |
| Exact Sciences Corporation | $143.72 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $128.38 | 2019-2025 | Krystexxa, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $121.33 | 2024-2025 | |
| Abbott Laboratories | $85.95 | 2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.54 | 2019-2024 | Xifaxan, Trulance |
| Shield Therapeutics INC | $64.13 | 2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $57.06 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $57.01 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Amarin Pharma, INC. | $54.31 | 2019 | |
| Alk-Abello, INC | $48.17 | 2019 | |
| Sanofi Pasteur INC. | $46.48 | 2024-2025 | |
| Lundbeck LLC | $43.68 | 2024-2025 | Rexulti |
| Sumitomo Pharma America, INC. | $43.16 | 2025 | Gemtesa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $30.97 | 2024 | Caplyta |
| Novartis Pharmaceuticals Corporation | $29.30 | 2020-2023 | |
| Genentech USA, INC. | $26.58 | 2019 | |
| Abbvie INC. | $17.49 | 2025 | |
| Currax Pharmaceuticals LLC | $13.47 | 2024 | Contrave |
| Kowa Pharmaceuticals America, INC. | $12.83 | 2023 | Livalo, Seglentis |
| Insulet Corporation | $12.68 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Indira Asser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.